Beximco Pharmaceuticals PLC. (R2WA.SG)
Stuttgart · EUR · Healthcare · Drug Manufacturers - Specialty & Generic
€0.62 (+0.00%) as of
Key statistics
- Market cap
- 430.36M
- P/E (TTM)
- 4.43
- EPS (TTM)
- 0.1400
- Dividend yield
- 5.39%
- 52-week range
- 0.3800 – 0.7900
- Beta
- 0.30
- Profit margin
- 16.04%
About Beximco Pharmaceuticals PLC.
Beximco Pharmaceuticals PLC. manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh and internationally. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to other companies. It offers products in various dosage forms, including solid, liquid, cream and ointment, suppositories, metered dose and dry powder inhaler, nasal spray, sterile, lyophilized injectable, and large volume intravenous fluids. Beximco Pharmaceuticals PLC. was incorporated in 1976 and is headquartered in Dhaka, Bangladesh.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Dhaka, Bangladesh
- Employees
- 6,000
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.